Two patients (one lung cancer and one stomach cancer) were treated with a CHEK2-targeted PARP-inhibitor: one patient had a stable disease followed by rapid progression, and one patient experienced progressive disease at first tumor evaluation. This evidence concerns the gene CHEK2 and lung cancer.